# Treatment of Participants With Advanced and/or Refractory Solid Tumors (MK-5108-001)

> **NCT00543387** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 35 (actual)

## Conditions studied

- Cancer, Neoplasms, Tumors

## Interventions

- **DRUG:** MK-5108
- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT00543387
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03-27
- **Primary completion:** 2011-04-04
- **Final completion:** 2011-04-04
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2024-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00543387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00543387, "Treatment of Participants With Advanced and/or Refractory Solid Tumors (MK-5108-001)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00543387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*